Comparative Analysis of the Quality of Life of Schizophrenic Patients between Combination Therapy of Risperidone-Haloperidol and Clozapine-Risperidone-Haloperidol in a Mental Health Hospital in West Kalimantan Province

Schizophrenia is one of the most complex mental disorders that can burden individuals and families, and it requires long-term treatment since it is a chronic disease that can potentially relapse. Therefore, this study compared the Health-Related Quality of life (HRQoL) of schizophrenic patients receiving a combination of antipsychotic therapy of risperidone and haloperidol (RH) antipsychotic therapy to clozapine, risperidone, and haloperidol (CRH). This was an observational cohort, prospective, pre-post observation study of schizophrenic inpatients at the Mental Hospital of West Kalimantan Province in the stable and discharge phases. Data were collected prospectively from March–May 2020, and consecutive sampling was conducted on 95 respondents. The Indonesian version of The 5-Level European Quality of Life 5 Dimensions (EQ5D-5L) questionnaire was filled by nurses and patients simultaneously to measure the HRQoL. The pre-therapy analysis performed at the stable phase using the Mann-Whitney test showed no difference in HRQoL between RH and CRH groups (p>0.05). Meanwhile, during the discharge phase (post-therapy), the HRQoL of the RH and CRH groups was not significantly different (p>0.05). The Wilcoxon test showed a significant difference in the RH and CRH groups from the beginning of the patients’ stable phase to the discharge (p<0.05). Therefore, there is a significant difference between RH and CRH combination therapy as well as the HRQoL improvement of schizophrenic patients.